{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:37:43Z","timestamp":1774921063567,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":10050,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1985,9]]},"abstract":"<jats:p>The pharmacodynamic interaction between midazolam and the specific benzodiazepine antagonist Ro 15\u20131788 has been investigated in six healthy male volunteers. Hypnotic steady\u2010state concentrations of midazolam (55 \u00b1 11 ng\/mL; mean \u00b1 SD) have been achieved rapidly by an intravenous bolus of 0.07 mg\/kg and maintained by an individual but constant infusion rate of 0.025 to 0.04 mg\/kg\/hr for eight hours. Following a two\u2010hour control period, the antagonist (2.5 mg) or the solvent were injected double\u2010blind in random order. Three hours later, the other medication was administered. Whereas plasma levels of midazolam remained constant throughout the complete eight\u2010hour trial (Clearance = 670 \u00b1 96 mL\/min) concentrations of Ro 15\u20131788 declined rapidly with an elimination half\u2010life between 0.7 and 1.8 hours and a total plasma clearance of 702 \u00b1 235 mL\/min. Concentrations of Ro 15\u20131788 approached the analytic limit of 2 ng\/mL within three hours. The pharmacodynamic response to midazolam and the antagonist was assessed by a sedation index using visual analogue scales, reaction time (RT) measurements, and transformed Fourier analysis of the power spectrum of the recorded electroencephalogram (EEG). About 30 to 45 seconds following the injection of Ro 15\u20131788, hypnotic action of midazolam was completely reversed as visualized by return to alpha rhythm in the EEG, shortening of prolonged RT, and normalization of the elevated sedation index. The antagonistic action lasted for about two to three hours. The abrupt arousal from sleep was not associated with any unpleasant sensations, however, three subjects experienced a profound perspiration for about ten minutes following the injection of Ro 15\u20131788. In conclusion, a small intravenous bolus of 2.5 mg Ro 15\u20131788 reverses rapidly the hypnotic action of midazolam. The relative short duration of the antagonistic effect is due to the fast hepatic elimination of Ro 15\u20131788, which might be a suitable antidote of benzodiazepine\u2010induced oversedation in special clinical situations.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1985.tb02866.x","type":"journal-article","created":{"date-parts":[[2013,3,9]],"date-time":"2013-03-09T00:43:22Z","timestamp":1362789802000},"page":"400-406","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacodynamic Interaction Between Midazolam and a Specific Benzodiazepine Antagonist in Humans"],"prefix":"10.1002","volume":"25","author":[{"given":"U.","family":"Klotz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.W.","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/290514a0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/294763a0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90251-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb04956.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02086.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427969"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609905"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02395217"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198428060-00002"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.217"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.133"},{"key":"e_1_2_1_13_2","first-page":"358","article-title":"Determination of the benzodiazepine antagonist Ro 15\u20131788 in plasma by high\u2010performance liquid chromatography with UV detection","volume":"33","author":"Timm U","year":"1983","journal-title":"Arzneimittelforsch"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198409050-00006"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02619.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976202184"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1019513"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-1-53"},{"key":"e_1_2_1_19_2","first-page":"627","article-title":"Die antagonistische Wirkung von Physostigmin auf die Sedierung durch Lormetazepam","volume":"30","author":"Grote B","year":"1981","journal-title":"Anaesthesist"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198307000-00010"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198110000-00016"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91373-3"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542513"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb10543.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1985.tb02866.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1985.tb02866.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:26:48Z","timestamp":1697758008000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1985.tb02866.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["10.1002\/j.1552-4604.1985.tb02866.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1985.tb02866.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}